|
US2020253960A1
|
|
Antibiotic formulations for treating of cavity infections
|
|
US2021007985A1
|
|
Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
|
|
WO2017123315A2
|
|
Nanocrystals formed in a microenvironment
|
|
US2016120806A1
|
|
Nanocrystals formed in a microenvironment
|
|
EP3129004A1
|
|
Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
|
|
US2015168432A1
|
|
Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals
|
|
AU2015244399A1
|
|
Liposomes that form drug nanocrystals after freeze-thaw
|
|
US2015071992A1
|
|
Concentrated, inhalable antibiotic formulation
|
|
AU2014340568A1
|
|
Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
|
|
US2014194502A1
|
|
Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
|
|
US2014194504A1
|
|
Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
|
|
US2014194503A1
|
|
Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
|
|
WO2014150245A1
|
|
Methods for inhalation of smoke-free nicotine
|
|
AU2012211514A1
|
|
Concentrated, inhalable ciprofloxacin formulation
|
|
US2011182831A1
|
|
Systems and methods used in conjunction with nicotine vaccines for effecting cessation of tobacco use
|
|
AU2010216348A1
|
|
pH-modulated formulations for pulmonary delivery
|
|
EP2330893A1
|
|
Deep lung pulmonary delivery of treprostinil
|
|
WO2009042212A2
|
|
Impinging jet nozzles in stretched or deformed substrates
|
|
US2009005423A1
|
|
Systems and methods for effecting cessation of tobacco use
|
|
CN101583354A
|
|
Systems for effecting cessation of tobacco use
|
